[ 1 ] WHO. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update—situation reports [Internet]. Geneva: World Health Organization; [cited 2021 Apr 30]. Available from: https://www.‍who.‍int/emergencies/diseases/novel-coronavirus-2019/situation-reports. 链接1

[ 2 ] Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod 2020;83(3):770‒803. 链接1

[ 3 ] Takizawa N, Yamasaki M. Current landscape and future prospects of antiviral drugs derived from microbial products. J Antibiot 2018;71(1):45‒52. 链接1

[ 4 ] Martinez JP, Sasse F, Brönstrup M, Diez J, Meyerhans A. Antiviral drug discovery: broad-spectrum drugs from nature. Nat Prod Rep 2015;32(1):29‒48. 链接1

[ 5 ] Bérdy J. Bioactive microbial metabolites. J Antibiot 2005;58(1):1‒26. 链接1

[ 6 ] Williams R, Hoehn M, inventors; ELI LILLY AND CO., assignee. Pyrazomycin and process for production. United States patent US 3802999. 1974 Sep 4.

[ 7 ] Sagar S, Kaur M, Minneman KP. Antiviral lead compounds from marine sponges. Mar Drugs 2010;8(10):2619‒38. 链接1

[ 8 ] Yoon JS, Kim G, Jarhad DB, Kim HR, Shin YS, Qu S, et al. Design, synthesis, and anti-RNA virus activity of 60-fluorinated-aristeromycin analogues. J Med Chem 2019;62(13):6346‒62. 链接1

[ 9 ] Kusaka T, Yamamoto H, Shibata M, Muroi M, Kishi T, Mizuno K. Streptomyces citricolor nov. sp. and a new antibiotic, aristeromycin. J Antibiot 1968;21(4):255‒63. 链接1

[10] Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. Practical Streptomyces genetics. Norwich: John Innes Foundation; 2000.

[11] Hong B, Phornphisutthimas S, Tilley E, Baumberg S, McDowall KJ. Streptomycin production by Streptomyces griseus can be modulated by a mechanism not associated with change in the adpA component of the A-factor cascade. Biotechnol Lett 2006;29(1):57‒64. 链接1

[12] Bierman M, Logan R, O’Brien K, Seno ET, Nagaraja Rao R, Schoner BE. Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp. Gene 1992;116(1):43‒9. 链接1

[13] Kohl M, Wiese S, Warscheid B. Cytoscape: software for visualization and analysis of biological networks. Methods Mol Biol 2011;696(696):291‒303.

[14] Yin J, Ma L, Wang H, Yan H, Hu J, Jiang W, et al. Chinese herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza virus infection through activation of heme oxygenase-1. Acta Pharm Sin B 2017;7(6):630‒7. 链接1

[15] Pizzi M. Sampling variation of the fifty percent end-point, determined by the Reed-Muench (Behrens) method. Hum Biol 1950;22(3):151‒90.

[16] Zhong M, Wang HQ, Yan HY, Wu S, Gu ZY, Li YH. Santin inhibits influenza A virus replication through regulating MAPKs and NF-jB pathways. J Asian Nat Prod Res 2019;21(12):1205‒14. 链接1

[17] Wang H, Zhang D, Ge M, Li Z, Jiang J, Li Y. Formononetin inhibits enterovirus 71 replication by regulating COX-2/PGE2 expression. Virol J 2015;12(1):35. 链接1

[18] Jiang Z, Li X, Ren W, Shi Y, Gao R, Li Y, et al. Discovery of siderophore compounds using genome mining strategy. Chin Med Biotechnol 2019;14(2):97‒107. Chinese.

[19] Escolar L, Pérez-Martín J, de Lorenzo V. Opening the iron box: transcriptional metalloregulation by the Fur protein. J Bacteriol 1999;181(20):6223‒9. 链接1

[20] Maxson T, Tietz JI, Hudson GA, Guo XR, Tai HC, Mitchell DA. Targeting reactive carbonyls for identifying natural products and their biosynthetic origins. J Am Chem Soc 2016;138(46):15157‒66. 链接1

[21] Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, et al. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. Nat Biotechnol 2016;34(8):828‒37.

[22] Lai CJS, Zha L, Liu DH, Kang L, Ma X, Zhan ZL, et al. Global profiling and rapid matching of natural products using diagnostic product ion network and in silico analogue database: Gastrodia elata as a case study. J Chromatogr A 2016;1456:187‒95.

[23] Wang Q, Zhang Y, Wang M, Tan Y, Hu X, He H, et al. Neo-actinomycins A and B, natural actinomycins bearing the 5H-oxazolo[4,5-b]chromophorephenoxazine, from the marine-derived Streptomyces sp. IMB094. Sci Rep 2017;7(1):3591. 链接1

[24] Fujii K, Ikai Y, Oka H, Suzuki M, Harada KI. A nonempirical method using LC/MS for determination of the absolute configuration of constituent amino acids in a peptide: combination of Marfey’s method with mass spectrometry and its practical application. Anal Chem 1997;69(24):5146‒51. 链接1

[25] Hamano K, Tanzawa K, Takahashi M, Enokida R, Okazaki H, Kinoshita T, et al., inventors; SANKYO Co., Ltd., assignee. Chymostatinols manufacture with Streptomyces for treatment of osteoporosis. Japanese patent JP 08003188 A. 1996 Jan 9.

[26] Konda Y, Takahashi Y, Arima S, Sato N, Takeda K, Dobashi K, et al. First total synthesis of Mer-N5075A and a diastereomeric mixture of a and b-MAPI, new HIV-I protease inhibitors from a species of Streptomyces. Tetrahedron 2001;57(20):4311‒21. 链接1

[27] Hoebeke J, Busatto-Samsoen C, Davoust D, Lebrun E. 1H NMR study of the diastereomeric forms of the protease inhibitor antipain. Magn Reson Chem 1994;32(4):220‒4. 链接1

[28] Jiang P. Preliminary research on antiviral drugs and vaccines [dissertation]. Beijing: Peking University; 2005. Chinese.

[29] Nothias LF, Nothias-Esposito M, da Silva R, Wang M, Protsyuk I, Zhang Z, et al. Bioactivity-based molecular networking for the discovery of drug leads in natural product bioassay-guided fractionation. J Nat Prod 2018;81(4):758‒67. 链接1

[30] Kim ES. Midostaurin: first global approval. Drugs 2017;77(11):1251‒9. 链接1

[31] Suda H, Aoyagi T, Hamada M, Takeuchi T, AntipainUmezawa H., a new protease inhibitor isolated from actinomycetes. J Antibiot 1972;25(4):263‒6. 链接1

[32] Umezawa H, Aoyagi T, Morishima H, Kunimoto S, Matsuzaki M, Hamada M, et al. Chymostatin, a new chymotrypsin inhibitor produced by actinomycetes. J Antibiot 1970;23(8):425‒7. 链接1

[33] Umezawa H, Aoyagi T, Okura A, Morishima H, Takeuchi T, Okami Y. Letter: elastatinal, a new elastase inhibitor produced by actinomycetes. J Antibiot 1973;26(12):787‒9. 链接1

[34] Appleyard G, Tisdale M. Inhibition of the growth of human coronavirus 229E by leupeptin. J Gen Virol 1985;66(2):363‒6. 链接1

[35] Molla A, Hellen CU, Wimmer E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J Virol 1993;67(8):4688‒95. 链接1

[36] Tashiro M, Klenk HD, Rott R. Inhibitory effect of a protease inhibitor, leupeptin, on the development of influenza pneumonia, mediated by concomitant bacteria. J Gen Virol 1987;68(7):2039‒41. 链接1